Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab plus multimodal radiotherapy in recurrent or metastatic nasopharyngeal carcinoma after multiple prior therapies
ChiCTR2100047112Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in nasopharyngeal carcinoma (NPC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Started Jun 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100047112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047112.